Twice-daily rTMS for Depressed Youth in Hospital
Official title: Seamless Integration of Repetitive Transcranial Magnetic Stimulation (rTMS) for Youth Inpatients With Depression: A Feasibility Study
Run by Sunnybrook Health Sciences Centre · NCT07140575 · Data updated 2026-11-12
This project will test whether giving twice-daily repetitive transcranial magnetic stimulation (rTMS) to hospitalized adolescents with moderate-to-severe depression is feasible while they attend on-unit schooling and receive therapeutic support.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 14 Years to 19 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Sunnybrook Health Sciences Centre Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | August 2025 |
| Main results expected | July 2027 |
| Study ends | December 2027 |
| Registry record updated | August 24, 2025 |
| Trial ID | NCT07140575 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adolescents (about 14–19 years) hospitalized or eligible for elective admission with a primary major depressive episode (or bipolar depression without psychotic/mixed features), a current episode of at least 4 weeks, GRID-HAMD-17 ≥16, and prior nonresponse to at least one evidence-based psychotherapy or antidepressant.
✕Probably not a fit
Patients with a history of psychotic disorders, recent substance use disorder, active mania or psychosis, epilepsy or other seizure disorders, pregnancy or nursing, eating disorders as the primary diagnosis, or taking medications that lower the seizure threshold are unlikely to be eligible or benefit from this pathway.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center feasibility project offers an accelerated rTMS pathway for adolescents admitted with major depressive episodes, delivering rTMS twice daily while participants engage in inpatient schooling and therapeutic programming. Eligible participants are typically aged 14–19 with moderate-to-severe depression (GRID-HAMD-17 ≥16) who have not responded to at least one evidence-based psychotherapy or antidepressant. The study will monitor feasibility, tolerability, safety, and depressive symptom change using standard rating scales and clinical observation. The protocol is informed by prior rTMS work in youth and accelerated rTMS pilots in adults, but focuses specifically on the inpatient setting to address access and logistical barriers.
Why it matters
Potential benefit: If successful, this pathway could let hospitalized youth receive accelerated rTMS with fewer travel and schooling disruptions and faster access to neuromodulation for difficult-to-treat depression.
How similar studies have gone: rTMS has shown benefit in adolescents and young adults with treatment-resistant depression, and accelerated twice-daily protocols have been piloted in adults with encouraging safety and similar effectiveness, but data specifically for inpatient youth remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age 14-19 years * primary diagnosis of major depressive disorder or of bipolar I or II disorder, current episode depressed with no psychotic or mixed features * current episode of depression lasting at least 4 weeks * failed ≥1 evidence-based psychotherapy or antidepressant * have a GRID-HAMD-17 (17-item Hamilton Depression Rating Scale) score of ≥16 (moderate-severe range) * currently an inpatient or suitable for an elective inpatient admission Exclusion Criteria: * lifetime diagnosis of a psychotic disorder, anorexia nervosa, bulimia nervosa diagnosis of a substance use disorder (except caffeine and tobacco) within the past year * obsessive compulsive disorder or personality disorder that is the main source and driver of distress * active psychosis and/or mania * history of epilepsy or any other neurologic condition that includes a history of seizures * use of medications that lower the seizure threshold * pregnancy or nursing * history of severe headaches within the previous year * improvement in depressive symptom severity between screening and baseline by 25% or more * inability to adhere to the protocol
Where it's running
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Automated ABPI for Peripheral Artery Disease: A Pilot Look at Two Devices
This pilot checks if two automated ankle-brachial pressure index devices can reliably detect PAD across symptom levels and after bypass surgery, using patient and clinician feedback for practicality.
-
AI-powered personalized exercise plan for older adults using a wearable app
A wearable-enabled, AI-driven exercise app is tested to see if it’s feasible and acceptable for adults 65+ and whether it can help increase activity, improve mood, and boost quality of life.
-
EEG microstates and inflammatory markers in treatment-resistant depression patients undergoing ECT
This study tests how electroconvulsive therapy affects brain activity patterns seen in EEG and inflammatory biomarkers in adults with treatment-resistant major depression.
-
EEG microstates and inflammatory biomarkers in older adults with major depression receiving ECT
This study tests how ECT affects brain wave patterns and inflammatory markers in people 55 and older with major depression.
-
Behavioral program to help depressed nursing home residents see if it helps
This study tests the InSTILL program to see if it is feasible, satisfactory, and helpful for residents of skilled nursing facilities who have depressive symptoms.
-
Central venous catheter placement with bedside ECG guidance and thoracic ultrasound
This study tests whether using intracavity ECG to confirm catheter tip position and bedside ultrasound to check for pneumothorax is feasible compared with standard post-procedure X-rays.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.